SolidSeq Actionable Gene Panel (22 Genes)

The SolidSeq Actionable Gene Panel is an advanced next-generation sequencing (NGS) based test that analyses 22 clinically significant genes in solid tumour samples to identify actionable mutations that can directly guide cancer treatment decisions. Solid tumours - which include cancers of the lung, breast, colon, liver, pancreas, and many other organs - often carry specific genetic mutations that act as drivers of cancer growth and progression. By examining these 22 carefully selected genes, the SolidSeq panel focuses specifically on mutations that are “actionable,” meaning they are associated with approved targeted therapies, immunotherapy options, or eligibility for clinical trials. This makes it a highly focused and clinically purposeful test, as opposed to broader sequencing panels that may generate large amounts of genetic data with limited immediate clinical relevance. The SolidSeq Actionable Gene Panel essentially helps oncologists match the right treatment to the right patient based on the unique genetic fingerprint of their tumour.

Who Should Get This Test Done?

The SolidSeq Actionable Gene Panel is recommended for individuals who:

●      Have been diagnosed with a solid tumour such as lung, breast, colorectal, gastric, ovarian, or liver cancer

●      Are being assessed for eligibility for targeted therapy or immunotherapy based on tumour genetics

●      Have not responded to standard first-line chemotherapy and require alternative treatment options

●      Are being considered for enrolment in a clinical trial that requires molecular profiling

●      Have a rare solid tumour where standard treatment protocols are limited or unclear

Why Consider This Test?

Targeted cancer therapy has transformed the way many solid tumours are treated, but its effectiveness depends entirely on whether the tumour carries the specific genetic mutation that the therapy is designed to target. The SolidSeq Actionable Gene Panel is designed with this clinical reality in mind - by focusing on 22 genes that have well-established therapeutic relevance, it delivers results that can be directly translated into treatment action without unnecessary complexity. For patients who have exhausted standard treatment options, identifying an actionable mutation through this panel can open the door to targeted drugs or immunotherapy that may offer significantly better outcomes. The panel also helps avoid the use of therapies that are unlikely to work for a particular tumour’s genetic profile, sparing patients from unnecessary side effects and treatment burden.

More Information

The test uses next-generation sequencing technology to simultaneously analyse all 22 genes in the panel for a range of genetic alterations including point mutations, insertions, deletions, copy number variations, and gene fusions. Results are typically available within one to two weeks (Terms and conditions apply) and are presented in a structured clinical report that clearly highlights actionable findings along with associated therapy options and relevant clinical evidence. The report is best reviewed by a treating oncologist or a multidisciplinary molecular tumour board to ensure that the findings are interpreted accurately within the broader context of the patient’s diagnosis, treatment history, and overall health status. It is worth noting that the availability of specific targeted therapies based on the panel findings may vary depending on regulatory approvals and institutional protocols at the time of testing.

Other Names

●      SolidSeq 22 Gene Panel

●      Solid Tumour Actionable Mutation Panel

●      Targeted Solid Tumour NGS Panel

●      22 Gene Cancer Sequencing Panel

●      Solid Tumour Molecular Profiling Test

●      Actionable Oncogene Panel

●      Solid Tumour Targeted Gene Panel